Code intelligence

FDA-NDA203441 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA203441.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: GATTEX (TEDUGLUTIDE) — Type 1 - New Molecular Entity

Policy FDA-NDA203441 · Gastroenterology

Critical

Gattex (teduglutide) is a subcutaneously administered GLP-2 analog approved for short bowel syndrome, an orphan indication. Given its subcutaneous route of administration and the fact that self-admini

View alert

Audit documentation

Building an audit file that includes FDA-NDA203441?

The Tripwire Audit Pack exports 12 months of Gastroenterology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Gastroenterology audit pack — $349One-time purchase · not a subscription